EPB-101 is EndoPel’s lead AI-engineered endolysin candidate, designed for the topical treatment of canine pyoderma caused by S. pseudintermedius.
EPB-101 is a formulated biologic that combines multiple AI-engineered chimeric endolysins into a single topical product. Each chimera was computationally designed using our proprietary AI platform and selected for activity against clinical S. pseudintermedius isolates, including methicillin-resistant (MRSP) strains.
By combining several enzymes that attack distinct, conserved bonds in the bacterial cell wall, EPB-101 delivers rapid, species-specific killing while making single-mutation resistance mechanistically implausible — and preserves the beneficial microbiome that broad-spectrum antibiotics destroy.
EPB-101 — a formulated mix of AI-engineered chimeric endolysins. Representative 3D protein structure showing surface topology and secondary structure elements.
Our pipeline focuses on topical endolysin formulations targeting the most prevalent bacterial infections in companion animals, with our lead program addressing canine pyoderma caused by S. pseudintermedius.
| Program | Indication | Target Pathogen | Formulation | Stage |
|---|---|---|---|---|
| EPB-101 | Canine Pyoderma | S. pseudintermedius | Topical Gel | Preclinical |
| EPB-102 | Canine Otitis Externa | S. pseudintermedius | Otic Solution | Lab Testing |
| EPB-103 | Wound Infections | Staphylococcus spp. | Topical Spray | Discovery |
| EPB-200 | Feline Infections | S. felis / S. aureus | TBD | Planning |
